

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/764,161	01/23/2004	John McMichael	13024/38629A	8158
4743 7:	590 06/30/2006		EXAMINER	
MARSHALL, GERSTEIN & BORUN LLP			WINSTON, RANDALL O	
	233 S. WACKER DRIVE, SUITE 6300 SEARS TOWER CHICAGO, IL 60606		ART UNIT	PAPER NUMBER
CHICAGO, IL			1655	
			DATE MAILED: 06/30/2000	5

Please find below and/or attached an Office communication concerning this application or proceeding.

T gr 3	Application No.	Applicant(s)			
° (10/764,161	MCMICHAEL ET AL.			
Office Action Summary	Examiner	Art Unit			
	Randall Winston	1655			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	L. lety filed the mailing date of this communication.			
Status					
 1) ⊠ Responsive to communication(s) filed on <u>01 Ja</u> 2a) ☐ This action is FINAL. 2b) ⊠ This 3) ☐ Since this application is in condition for allowar closed in accordance with the practice under E 	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) <u>1-47</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-47</u> are subject to restriction and/or expending in the application.	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated any not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the bed on the ledge of the le	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received. s have been received in Applicati nty documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Application/Control Number: 10/764,161 Page 2

Art Unit: 1655

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, drawn to a method of alleviating symptoms of a connective tissue disorder selected from different disease and/or disorder states, classified in class 514, subclass 12, for example
- II. Claims 11-15, drawn to a method of alleviating symptoms of a connective tissue disorder in bovines from the disorder of mastitis, classified in class 424, subclass 442, for example.
- III. Claims 16-23, drawn to a pharmaceutical composition for administering to a subject for alleviating symptoms of a connective tissue disorder comprising streptolysin o, classified in class 424, subclass 439, for example.
- IV. Claims 24-32, drawn to a method of alleviating symptoms of reproductive fibrosis conditions, classified in class 514, subclass 1, for example.
- V. Claims 33-40, drawn to a method of protecting nerve cells in a subject from the effects of neurotoxic agents, classified in class 424, subclass 442, for example.
- VI. Claims 41-47, drawn to a method of inhibiting CD44 receptor mediated processes, classified in class 514, subclass 1, for example.
- 2. The inventions are distinct from each other because of the following reasons:

Art Unit: 1655

Inventions III and I,II,IV,V,VI are related as product (i.e. III) and process of use (i.e. I,II,IV,V,VI). The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). In the instant case, the product as claimed (i.e. streptolysin o) can be used in a materially different process of using that product such as for the treatment of motor deficit disorders instead of the claimed disorders.(see, e.g. McMichael et al. US 630127, see e.g. column 2 lines 34-43)

- Inventions I,II,IV,V,VI are related as different methods of using. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP 806.04, MPEP 808.01). In the instant case, they are different inventions because they utilize different claimed steps to obtain different claimed preambles and/or to alleviate different claimed disorders.
- They have acquired a separate status in the art as separate subject for inventive effect and require independent searches. The search for each of the above inventions is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate the invention of one group would not necessarily anticipate or even make obvious another group. Finally the consideration for patentability is different in

Application/Control Number: 10/764,161

Art Unit: 1655

each case. Thus, it would be an undue burden to examine all the above inventions in one application.

Furthermore for Group I and III, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

The claimed species are:

a) Dupuytren's contracture b) scleroderma c) Peyronie's disease d) claudication due to peripheral arterial disease

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for Group I and III a-d above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

For Group IV, the claimed species are:

a) uterine fibrosis b) fallopian tube fibrosis

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for Group IV from the list of a-b above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that the reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which a written in dependent form or otherwise include all the limitations of allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a)

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be completed must include an election of the invention to be examined even though the requirements be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Randall Winston whose telephone number is 571-272-0972. The examiner can normally be reached on 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/764,161 Page 6

Art Unit: 1655

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SUSAN COE PRIMARY EXAMINER